Immuneering Corp
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $0 | $316,952 | $2.1M |
| Cost of revenue | — | — | $0 | $158,122 | $1.2M |
| Gross profit | — | — | $0 | $158,830 | $926,888 |
| Research and development | $42.0M | $48.0M | $41.6M | $36.3M | $26.5M |
| Operating expenses | $59.4M | $64.1M | $58.4M | $51.9M | $34.8M |
| Operating income | -$59.4M | -$64.1M | -$58.4M | -$51.7M | -$33.9M |
| Pretax income | — | — | — | -$50.5M | -$33.8M |
| Income tax expense | $0 | — | — | — | -$307,485 |
| Net income | -$56.0M | -$61.0M | -$53.5M | -$50.5M | -$33.5M |
| Balance Sheet | |||||
| Cash and equivalents | $128.6M | $36.1M | $59.4M | $72.6M | $74.9M |
| Current assets | $176.2M | $39.6M | $89.1M | $108.7M | $152.3M |
| Total assets | $232.0M | $52.7M | $102.6M | $122.4M | $166.7M |
| Current liabilities | $10.1M | $7.5M | $7.8M | $8.1M | $5.6M |
| Total liabilities | $13.5M | $11.3M | $12.0M | $12.5M | $10.7M |
| Stockholders' equity | $218.5M | $41.4M | $90.6M | $109.9M | $156.0M |
| Cash Flow Statement | |||||
| Cash from operations | -$45.3M | -$55.0M | -$49.0M | -$44.1M | -$30.9M |
| Depreciation and amortization | $324,517 | $355,807 | $322,816 | $247,199 | $45,467 |
| Stock-based compensation | $6.3M | $6.5M | $5.7M | $4.1M | $1.8M |
| Capital expenditure | $142,226 | $84,875 | $342,746 | $742,483 | $60,786 |
| Free cash flow | -$45.5M | -$55.1M | -$49.3M | -$44.8M | -$30.9M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 64.7M · Free float 79.7%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.